Stem cells can change inflammation by altering immune-cell activity. Mesenchymal stromal cells (MSCs), the cells used in many inflammation studies, release signals that can slow T-cell activation, support regulatory immune cells, and change how macrophages respond to damaged tissue. These effects depend on the inflammatory environment; MSCs do not simply switch inflammation off. Much of the mechanism evidence comes from laboratory and animal studies, not proof of benefit in people. 29895977PMC10040934
Human results depend on the exact product and disease. Ryoncil is approved by the U.S. Food and Drug Administration (FDA) for steroid-refractory acute graft-versus-host disease (GVHD) in children aged 2 months and older. In its single-arm trial, 38 of 54 children responded at day 28, while 65% had a serious adverse reaction. Its label says the mechanism of action is not clear. Approval for this condition does not validate a general “stem cell infusion for inflammation.” Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus hostFdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display

Which stem cells affect inflammation?
MSCs are cell populations obtained from tissues such as bone marrow, fat, and umbilical cord. They can come from the patient (autologous) or from a donor (allogeneic). Their immune effects vary with cell source, preparation, and surrounding inflammatory signals; results from one product cannot be assumed for another. PMC10040934
Blood-forming stem cells (HSCs) rebuild blood and immune-cell production after intensive treatment. HSC transplantation is a different procedure from an MSC injection. It can involve high-dose chemotherapy, prolonged immune recovery, and risks including infection, infertility, organ damage, and secondary cancers. The National Cancer Institute also notes its use in autoimmune disease, but that does not make it a routine treatment for an elevated inflammatory marker. Stem cell transplant
Inflammation itself helps defend against infection and repair injury. A prolonged or misdirected response can damage tissue, but suppressing every immune response would not be desirable. This is why an anti-inflammatory laboratory result is not enough to decide whether a treatment will help a particular person. 29895977
How MSCs change immune activity
Responding to inflammatory signals
MSCs do not continuously release the same anti-inflammatory mixture. In experimental systems, interferon-gamma (IFN-γ), together with tumor necrosis factor-alpha (TNF-α) or interleukin-1 (IL-1), can activate their immunosuppressive functions. This response is often called “licensing.” Under other conditions, MSCs may have weaker suppressive effects or promote immune-cell recruitment. 29895977PMC10040934
A high C-reactive protein (CRP) result indicates inflammation but does not identify its cause or location. It needs to be interpreted alongside symptoms, medical history, and other tests. It is not a test of suitability for MSC treatment. C reactive protein crp test
Slowing T cells and supporting immune regulation
Human MSCs can express indoleamine 2,3-dioxygenase (IDO), an enzyme that breaks down tryptophan. Reduced tryptophan availability and the resulting metabolites can limit T-cell multiplication. MSCs also produce prostaglandin E2 (PGE2) and can support regulatory T cells (Tregs), which restrain immune responses. Human MSCs rely more on IDO, while mouse MSCs use nitric-oxide pathways more prominently—an important limit when interpreting animal results. PMC10040934
In some experiments, MSCs trigger apoptosis, or programmed cell death, in activated T cells. Macrophages then engulf those cells and release transforming growth factor-beta (TGF-β), which can further support Tregs. These are proposed routes of immune regulation, not proof that each pathway explains a patient's clinical response. PMC10040934
Changing macrophage behavior
Macrophages help clear microbes and damaged cells. Experimental MSC treatments can shift them toward less inflammatory, more repair-associated behavior, often described as an “M2-like” rather than “M1-like” state. These labels simplify a wider range of cell states. Studies also describe increased interleukin-10 (IL-10) and clearance of apoptotic cells, called efferocytosis. PMC10040934
Clearing dead cells may help resolve inflammation. It does not, by itself, demonstrate cartilage regrowth, reversal of organ damage, or symptom relief in people.
Other immune cells and extracellular vesicles
Laboratory studies describe effects on B-cell growth, antibody production, natural killer cells, and dendritic cells. MSCs also release extracellular vesicles (EVs): membrane-bound packages carrying proteins, RNA, and other molecules. EVs can reproduce some immune effects in experimental models, but a vesicle preparation is not interchangeable with a tested living-cell product. PMC10040934
In some animal models, the death and subsequent engulfment of infused MSCs contribute to immune suppression. Long-term cell survival is therefore not always necessary for an experimental effect. This does not establish a human dosing schedule or justify claims that commercially offered exosomes will treat inflammation. PMC10040934
Why the route and dose matter
An injection into a joint, a local injection around a fistula, and an intravenous infusion expose cells to different tissues. Evidence from one route cannot establish benefit through another.
Ryoncil's initial regimen is 2 × 106 cells/kg intravenously twice weekly for four weeks—eight infusions. Additional treatment depends on response. Its label reports no pharmacokinetic studies, so it does not establish a human distribution or persistence profile. A larger cell dose is not automatically more effective. FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display
The same label reports blood-sample findings in 40 children aged 0.6–17 years: TNFR1 and ST2, two inflammatory biomarkers, were 79% and 75% lower at day 180 than at baseline. These observations do not prove that the biomarker changes caused the clinical response, and they cannot predict the effects of another cell product. FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display
What human studies show
Clinical response, fistula closure, pain scores, and survival are different outcomes. None is a universal “stem cell success rate,” and improvement in one does not necessarily demonstrate suppression of a particular inflammatory pathway.
| Condition and population | Cells, route, and study | Findings | What limits the conclusion |
|---|---|---|---|
| Pediatric steroid-refractory acute GVHD after donor HSC transplantation | Ryoncil, donor bone marrow MSCs; intravenous 2 × 106 cells/kg twice weekly for four weeks initially; prospective multicenter single-arm study, 54 treated | Day-28 overall response 38/54 (70%); complete response 16/54 (30%); median response duration 54 days | No concurrent control or randomized survival comparison; serious adverse reactions in 35/54 (65%). U.S. approval is specific to this product and indication. Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus hostFdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display |
| Adults with treatment-refractory complex perianal Crohn's fistulas | Original phase 3 ADMIRE-CD: donor adipose-derived MSCs, darvadstrocel; single local dose of 120 million cells with fistula preparation; 212 randomized | Week-24 combined remission: 53/107 (50%) versus 36/105 (34%); reported absolute difference 15.2 percentage points | Local adjunct, not systemic Crohn's treatment; treatment-related adverse events 17% versus 29%. Later confirmatory findings were negative. 27477896 |
| Adults with complex perianal Crohn's fistulas | Phase 3 ADMIRE CD II: darvadstrocel, same local cell dose; both groups received curettage and closure of internal openings; 568 randomized | Week-24 combined remission: 48.8% versus 46.3%; estimated difference 2.4 percentage points (95% CI −5.8 to 10.6); p = 0.571 | Primary endpoint not met; no significant benefit on key secondary endpoints. Treatment-emergent adverse events occurred in 73.0% versus 73.4% of safety populations; no new safety signals. 41790076 |
| Adults with knee osteoarthritis | Cao et al.: meta-analysis of eight randomized trials, 502 participants; intra-articular MSCs, varied sources and doses | Reported between-group WOMAC differences favored MSCs by 7.44 points at six months and 10.31 at 12 months | Symptom/function outcomes, varied comparators and preparations; not proof of cartilage regeneration or a direct measure of inflammation. PMC11887158 |
| Mechanically ventilated adults with moderate or severe COVID-19 acute respiratory distress syndrome (ARDS) | Phase II/III randomized sham-controlled trial; 222 patients; two intravenous doses of donor MSCs at 2 × 106 cells/kg | Thirty-day mortality: 42/112 (37.5%) versus 47/110 (42.7%); relative risk 0.88 (95% CI 0.64–1.21), p = 0.43 | Enrollment stopped early for futility; no significant difference in days alive off ventilation within 60 days; no infusion-related toxicities; serious adverse events similar over 30 days. PMC9896641 |
GVHD occurs when donor immune cells attack the recipient's tissues. The Ryoncil study enrolled patients with grades B–D disease, excluding grade B skin-only disease; the approved indication and the actual study population should not be confused. Its 54-day median response duration was measured from day-28 response to progression, new systemic GVHD therapy, or death—not a guarantee of lasting remission. FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display
Crohn's findings did not consistently replicate
The original ADMIRE-CD endpoint combined closure of draining external fistula openings with no collections larger than 2 cm on MRI. A small extension reported clinical remission at 104 weeks in 56% versus 40%, but only 40 patients entered that extension and there was no MRI assessment at that time. 2747789634890373
The larger ADMIRE CD II trial did not confirm superiority over placebo. In December 2024, the European Medicines Agency reported that the benefits of Alofisel, the darvadstrocel product, were no longer demonstrated and announced withdrawal from the EU market. This is an EU regulatory outcome, not a statement about Japanese authorization. The earlier positive trial should not be presented on its own as settled evidence of benefit. 41790076Alofisel withdrawn eu market
Knee symptom improvement is not cartilage repair
WOMAC and KOOS measure knee symptoms and function; VAS measures pain. In Cao et al., the six-month WOMAC estimate was 7.44 points (95% CI 1.45–13.42), and the 12-month estimate was 10.31 (95% CI 0.96–19.67). Exploratory subgroup findings do not establish the best cell source or dose. PMC11887158
A broader 2025 Cochrane review included 25 trials and 1,341 participants, with eight placebo-controlled trials involving 459 participants. Compared with placebo, pain was about 1.2 points better on a 0–10 scale at up to six months (95% CI 0–2.5 points better; seven studies, 445 participants). The evidence for pain and function was low certainty; safety remained uncertain because serious adverse events were infrequently reported. No included study assessed radiographic progression. PMC11961299
For knee osteoarthritis, these findings concern possible symptom relief. They do not establish cartilage regrowth, control of a specific inflammatory mechanism, or predictable benefit for an individual patient. The two reviews used different eligibility criteria and comparisons, so their numerical estimates should not be treated as directly interchangeable. PMC11887158PMC11961299
Can cell treatment worsen inflammation or cause harm?
Yes. Immune modulation can be unwanted, and cell products can cause infusion reactions or transmit infection. Safety depends on the exact product and procedure, not simply on whether cells are described as natural or taken from the patient.
- Infection and contamination: Ryoncil's label warns of infectious-agent transmission despite donor screening and testing. Collection and processing controls matter. FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display
- Infusion reactions: Serious hypersensitivity, including anaphylaxis, can occur. Ryoncil contains dimethyl sulfoxide (DMSO) and may contain traces of porcine or bovine proteins; reactions to those components are product-specific risks. FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display
- Unwanted tissue formation: Ryoncil's label warns about possible ectopic tissue formation. This is not the same as evidence that a treatment rebuilds damaged tissue where desired. FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display
- Uncertain long-term safety: A small trial or few reported adverse events cannot exclude uncommon or delayed harms. Cochrane found the knee-injection safety evidence uncertain. PMC11961299
- Unapproved products and delayed care: FDA warns that human-cell and tissue products requiring but lacking approval have not had their quality, safety, purity, or potency verified by the agency. Trying an unproven product can also delay appropriate diagnosis and established treatment. Patient and consumer warning about potential serious risks harm following use unapproved products
The 65% serious-adverse-reaction figure for Ryoncil came from seriously ill children with steroid-refractory GVHD. It should neither be presented as the risk of every MSC treatment nor dismissed when discussing that product. FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display
What Japanese registration does—and does not—show
For treatments covered by Japan's Act on the Safety of Regenerative Medicine, providers must follow the applicable procedures, including committee review and submission of a provision plan. The framework also includes safety reporting. A filed plan is not marketing approval for a manufactured regenerative medical product and does not prove clinical efficacy. Index
PMDA publishes records of approved regenerative medical products. Product marketing approval and provision-plan procedures are separate routes; neither should be described as approval for every disease or for any product carrying a similar cell label. Ask which route applies to the exact proposed intervention. 0002
Applying the evidence to a consultation
A hypothetical situation: someone with knee pain is offered an intravenous infusion and shown a study of cells injected into a knee. That study does not establish benefit from the proposed intravenous treatment. The route, cell preparation, patient population, and outcome must match before the evidence can answer the person's question.
Take the written treatment proposal and the cited study to a qualified clinician. Compare these details:
| Detail to check | What to ask |
|---|---|
| Diagnosis and treatment goal | Is the goal less pain, lower inflammatory markers, fistula closure, or something else? How will it be measured? |
| Product and cell source | What is the exact product, and are the cells patient-derived or donor-derived? |
| Administration | Does the proposed dose, route, and schedule match the evidence? |
| Study quality and applicability | Was there a control group? What were the absolute benefits, harms, and follow-up time in people with this diagnosis? |
| Regulatory status and practical care | Is this an approved product, research intervention, or clinic service? Who handles complications, what does follow-up include, and what are the full costs? |
No individual response can be predicted from the trial averages above. Do not stop prescribed treatment to try a cell product without discussing it with the treating clinician.
Preparing for a consultation in Japan?
Ask about appointments, language support, and which medical records to prepare. A physician must assess diagnosis, suitability, and treatment options.
Bottom line
MSCs can alter inflammatory signaling and immune-cell behavior, but the biological mechanism does not guarantee clinical benefit. Ryoncil has a specific U.S. approval supported by a day-28 response study; a larger Crohn's fistula trial failed to confirm an earlier positive result; knee benefits remain uncertain and mainly symptom-based; and the cited COVID-19 ARDS trial found no significant mortality benefit. None supplies a universal timeline or success rate for “inflammation.” FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display41790076PMC11961299PMC9896641
This article provides general information, not individual medical advice. It does not report first-hand patient outcomes or substitute for assessment by a qualified clinician.
Disclosure: This website provides consultation and patient-support services. Its service links are not independent medical evidence, and no treatment outcome is guaranteed.
Sources
- Shi Y, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nature Reviews Nephrology. 2018;14:493–507. doi:10.1038/s41581-018-0023-5. https://pubmed.ncbi.nlm.nih.gov/29895977/. Accessed October 24, 2026.
- Li P, et al. Immunomodulatory properties of mesenchymal stem cells/dental stem cells and their therapeutic applications. Cellular & Molecular Immunology. 2023;20:558–569. doi:10.1038/s41423-023-00998-y. https://pmc.ncbi.nlm.nih.gov/articles/PMC10040934/. Accessed October 27, 2026.
- U.S. Food and Drug Administration. FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease. December 18, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-mesenchymal-stromal-cell-therapy-treat-steroid-refractory-acute-graft-versus-host. Accessed October 24, 2026.
- DailyMed, U.S. National Library of Medicine. Ryoncil (remestemcel-L-rknd): Full Prescribing Information. Revised September 2025. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a4e0918f-7444-4694-adeb-d38d98345659&type=display. Accessed October 27, 2026.
- National Cancer Institute. Stem Cell Transplants in Cancer Treatment. Updated October 5, 2023. https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant. Accessed October 24, 2026.
- MedlinePlus, U.S. National Library of Medicine. C-Reactive Protein (CRP) Test. https://medlineplus.gov/lab-tests/c-reactive-protein-crp-test/. Accessed October 27, 2026.
- Panés J, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. The Lancet. 2016;388:1281–1290. doi:10.1016/S0140-6736(16)31203-X. https://pubmed.ncbi.nlm.nih.gov/27477896/. Accessed October 27, 2026.
- Colombel JF, et al. Darvadstrocel in Patients With Crohn's Disease With Complex Perianal Fistulas: The ADMIRE CD II Phase 3 Randomized Trial. Gastroenterology. 2026;170:1562–1570. doi:10.1053/j.gastro.2025.12.033. https://pubmed.ncbi.nlm.nih.gov/41790076/. Accessed October 27, 2026.
- Cao M, et al. Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Research & Therapy. 2025;16:122. doi:10.1186/s13287-025-04252-2. https://pmc.ncbi.nlm.nih.gov/articles/PMC11887158/. Accessed October 27, 2026.
- Bowdish ME, et al. A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19. American Journal of Respiratory and Critical Care Medicine. 2023;207:261–270. doi:10.1164/rccm.202201-0157OC. https://pmc.ncbi.nlm.nih.gov/articles/PMC9896641/. Accessed October 27, 2026.
- Garcia-Olmo D, et al. Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease: ADMIRE-CD Phase 3 Randomized Controlled Trial. Diseases of the Colon & Rectum. 2022;65:713–720. doi:10.1097/DCR.0000000000002325. https://pubmed.ncbi.nlm.nih.gov/34890373/. Accessed October 24, 2026.
- European Medicines Agency. Alofisel withdrawn from the EU market. December 13, 2024. https://www.ema.europa.eu/en/news/alofisel-withdrawn-eu-market. Accessed October 27, 2026.
- Whittle SL, et al. Stem cell injections for osteoarthritis of the knee. Cochrane Database of Systematic Reviews. 2025;4:CD013342. doi:10.1002/14651858.CD013342.pub2. https://pmc.ncbi.nlm.nih.gov/articles/PMC11961299/. Accessed October 27, 2026.
- U.S. Food and Drug Administration. Patient and Consumer Warning about Potential Serious Risks of Harm following Use of Unapproved Products from Human Cells or Tissues. Content current as of May 11, 2026. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/patient-and-consumer-warning-about-potential-serious-risks-harm-following-use-unapproved-products. Accessed October 27, 2026.
- Ministry of Health, Labour and Welfare, Japan. Regenerative medicine, cell medicine, and gene therapy. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryou/saisei_iryou/index.html. Accessed October 27, 2026.
- Pharmaceuticals and Medical Devices Agency, Japan. List of Approved Products: New Regenerative Medical Products. https://www.pmda.go.jp/english/review-services/reviews/approved-information/0002.html. Accessed October 27, 2026.




